We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Funds to Boost British Efforts to Develop Chlamydia Vaccine

By LabMedica International staff writers
Posted on 16 Aug 2015
Print article
An infusion of new funding is expected to boost efforts by researchers in the United Kingdom to develop a vaccine to prevent Chlamydia infection.

Chlamydiae are small gram-negative obligate intracellular microorganisms that preferentially infect squamocolumnar epithelial cells. Chlamydia trachomatis infection, with nearly 200,000 new cases per year in the United Kingdom, is the most commonly reported bacterial sexually transmitted disease in the United States and a leading cause of infertility in women.

In a major effort to control the spread of chlamydial infection, the United Kingdom's Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; London, United Kingdom) has committed GBP 377,000 to aid in the development of a vaccine. The project will be conducted by Prokarium Ltd. (London, United Kingdom), a biotechnology company that develops transformational oral vaccines. Prokarium will add an additional 121,000 GBP to the research program.

The development effort will be shared by Prokarium and its collaborator, Dr. Robin Shattock, professor of mucosal infection and immunity at Imperial College London (United Kingdom). The plan is to complete the preclinical development of the Chlamydia vaccine in time for clinical trials in 2017.

Dr. Steve Chambers, CEO of SynbiCITE, said, "The new Prokarium vaccine was selected for funding because the need for a Chlamydia vaccine is significant and the potential for this approach both for Chlamydia and as a model for treating other infections in the medium-term is very encouraging.”

Dr. Steve Chatfield, chairman of Prokarium, said, “This SynbiCITE funding allows us to test a vaccine against the one of the world’s most serious sexually transmitted infections. Prokarium is now well set up to work with the best of the best in the vaccine arena.”

Related Links:

SynbiCITE
Prokarium Ltd.
Imperial College London


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.